Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

Summary

This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.

Timeline

Start

2017-12-04

Primary completion

2018-06-15

Completion

2018-06-15

Drugs

Indications